Payment overview · 2025
General Payments
$20,759.66
107 reported records · 19 companies
Healthcare provider profile · identity verified
Harry Balian, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · GLENDALE, CA · NPI 1427150952
Verified facts
What the public records show
CMS Open Payments records show Harry Balian, M.D. received $20,759.66 in general payments during 2025 across 107 reported records.
Abbott Laboratories accounted for 52.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 458 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 417 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 458 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $10,793.36 | 52.0% | 38 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $4,030.55 | 19.4% | 5 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $3,893.84 | 18.8% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$539.01 | 2.6% | 10 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $301.96 | 1.4% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $240.75 | 1.2% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $227.17 | 1.1% | 12 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $144.78 | 0.7% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $144.05 | 0.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $114.78 | 0.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.24 | 0.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.00 | 0.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.77 | 0.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $35.48 | 0.2% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $31.69 | 0.1% | 1 | 2025 |
| Nipro Medical Corporation | Unresolved — no canonical attribution shown | $23.45 | 0.1% | 1 | 2025 |
| MicroVention, Inc. | Unresolved — no canonical attribution shown | $20.91 | 0.1% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $18.31 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.56 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $8,750.00 | 4 |
| Consulting Fee | $4,440.00 | 4 |
| Food and Beverage | $3,819.66 | 98 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,750.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $7,321.12 | 6 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $3,750.00 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $3,010.00 | 2 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $2,500.00 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $430.00 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $301.96 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $274.31 | 5 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $251.28 | 3 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $240.75 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $227.17 | 12 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $217.31 | 3 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $202.56 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $194.73 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $184.13 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $160.69 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $144.78 | 7 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $116.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $114.78 | 4 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $110.73 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $104.48 | 6 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $96.92 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $84.59 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.24 | 3 | 2025 |
Source payment records
|
|||||
| NC TREK NEO Normalized: nc trek neo |
Device | Abbott Laboratories | $57.13 | 3 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $51.54 | 3 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| REVEAL LINQ Normalized: reveal linq |
Device | Medtronic, Inc. | $34.32 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $31.69 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| Hemodialysis System Normalized: hemodialysis system |
Device | Nipro Medical Corporation | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| CONFIANZA Normalized: confianza |
Device | Abbott Laboratories | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| STENT Normalized: stent |
Device | MicroVention, Inc. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| TRAILBLAZER Normalized: trailblazer |
Device | Medtronic, Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| HI-TORQUE PILOT Normalized: hi torque pilot |
Device | Abbott Laboratories | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| EMBOSHIELD NAV6 Normalized: emboshield nav6 |
Device | Abbott Laboratories | $6.93 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $4.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 458 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
458 | 81 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
417 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
458 | 81 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ranolazine Er | Ranolazine | 1936 | 259 |
| Metoprolol Succinate | Metoprolol Succinate | 838 | 126 |
| Clopidogrel | Clopidogrel Bisulfate | 813 | 152 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 660 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 604 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 552 | 80 |
| Eliquis | Apixaban | 458 | 81 |
| Carvedilol | Carvedilol | 436 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 81 |
| Entresto | Sacubitril/Valsartan | 417 | 63 |
| Brilinta | Ticagrelor | 373 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 348 | 61 |
| Multaq | Dronedarone Hcl | 285 | 42 |
| Furosemide | Furosemide | 273 | 53 |
| Lisinopril | Lisinopril | 266 | 47 |
| Clonidine | Clonidine | 265 | 43 |
| Prasugrel Hcl | Prasugrel Hcl | 252 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 39 |
| Clonidine Hcl | Clonidine Hcl | 225 | 35 |
| Repatha Sureclick | Evolocumab | 219 | 36 |
| Amiodarone Hcl | Amiodarone Hcl | 203 | 36 |
| Losartan Potassium | Losartan Potassium | 157 | 38 |
| Vascepa | Icosapent Ethyl | 152 | 26 |
| Xarelto | Rivaroxaban | 144 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 137 | 25 |
| Nitroglycerin | Nitroglycerin | 127 | 24 |
| Farxiga | Dapagliflozin Propanediol | 126 | 19 |
| Warfarin Sodium | Warfarin Sodium | 125 | 11 |
| Nifedipine Er | Nifedipine | 123 | 16 |
| Potassium Chloride | Potassium Chloride | 108 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 20 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 94 | 16 |
| Propranolol Hcl | Propranolol Hcl | 93 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 92 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 20 |
| Cilostazol | Cilostazol | 83 | 13 |
| Edarbi | Azilsartan Medoxomil | 80 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | suppressed |
| Digoxin | Digoxin | 71 | 11 |
| Gabapentin | Gabapentin | 61 | 15 |
| Flecainide Acetate | Flecainide Acetate | 59 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 57 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Spironolactone | Spironolactone | 50 | suppressed |
| Jardiance | Empagliflozin | 47 | 13 |
| Sotalol | Sotalol Hcl | 46 | suppressed |
| Irbesartan | Irbesartan | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Verquvo | Vericiguat | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Micardis | Telmisartan | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Benicar | Olmesartan Medoxomil | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Inpefa | Sotagliflozin | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Plavix | Clopidogrel Bisulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20,759.66 · 107 records | Abbott Laboratories | ACCOLADE SR, AURYON LASER SYSTEM 100-120 VAC, AVVIGO Guidance System, Assure WCD, CARDIOMEMS, CONFIANZA, COROFLOW, DIAMONDBACK PERIPHERAL, DRAGONFLY OPSTAR, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, EMBLEM MRI S-ICD, EMBOSHIELD NAV6, ESPRIT, EVOQUE, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, General - Vascular Access, HI-TORQUE PILOT, Hemodialysis System, IGT Devices Undivided, JARDIANCE, Kerendia, LEQVIO, LifeVest, MICRA, MITRACLIP, NC TREK NEO, OPTIS, PERCLOSE PROSTYLE, PRESSUREWIRE, PROTEGE RX, REVEAL LINQ, Repatha, SAPIEN 3 Ultra RESILIA, STENT, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRAILBLAZER, TRICLIP, VENASEAL, Venovo, WATCHMAN FLX, XACT, XIENCE SKYPOINT | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error